drugset / Trial / NCT03207867
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.
Timeline
- Start
- 2017-08-28
- Primary completion
- 2023-02-13
- Completion
- 2023-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIR178 | Unknown | 80 mg | Oral |
| Subject | NIR178 | Unknown | 160 mg | Oral |
| Subject | NIR178 | Unknown | 240 mg | Oral |
| Subject | Spartalizumab | Monoclonal antibody | 400 mg | Intravenous |